ADRIAMYCIN Drug Patent Profile
✉ Email this page to a colleague
When do Adriamycin patents expire, and what generic alternatives are available?
Adriamycin is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in ADRIAMYCIN is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adriamycin
A generic version of ADRIAMYCIN was approved as doxorubicin hydrochloride by PFIZER on December 23rd, 1987.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ADRIAMYCIN?
- What are the global sales for ADRIAMYCIN?
- What is Average Wholesale Price for ADRIAMYCIN?
Summary for ADRIAMYCIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for ADRIAMYCIN |
| DailyMed Link: | ADRIAMYCIN at DailyMed |
US Patents and Regulatory Information for ADRIAMYCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | ADRIAMYCIN PFS | doxorubicin hydrochloride | INJECTABLE;INJECTION | 063165-001 | Jan 30, 1991 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pfizer | ADRIAMYCIN PFS | doxorubicin hydrochloride | INJECTABLE;INJECTION | 063165-002 | Jan 30, 1991 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
